ABSTRACT #11522: Preliminary Results from FLAGSHP-1: A Phase 1 Study of ERAS-601 as a Monotherapy or in Combination with Cetuximab in Patients (pts) Previously Treated for Advanced Chordoma

<u>Mrinal M. Gounder¹, Ezra Rosen¹, Aparna R. Parikh², Anthony P. Conley³, Siddharth Sheth⁴, Nicholas Mai¹, Erica Sgroe¹, Ryan Mitchell¹, Roxana Picard⁵, Armend Lokku⁵, Les H. Brail⁵, Gregory M. Cote²</u> ¹Memorial Sloan Kettering Cancer Center, New York, NY; ²Mass General Cancer Center, Houston, TX; ⁴University of North Carolina, Chapel Hill, NC; ⁵Erasca, Inc., San Diego, CA

Background

- ERAS-601 is a potent, selective, and orally bioavailable allosteric inhibitor of SHP2 that inhibits RAS/MAPK signaling
- Chordoma, a rare tumor type with no approved therapies, has a genetic dependency for SHP2¹.
- ERAS-601 in combination with cetuximab showed promising preliminary safety and tolerability in solid tumor treatment²
- Chordoma cell lines were sensitive to SHP2 suppression and SHP2 inhibitors demonstrated antitumor activity in preclinical chordoma models¹.



Part D1: Combination Dose Escalation ERAS-601 BID (3/1)^a + cetuximab^b

> ERAS-601 **60 mg** BID (3/1) + cetuximab ERAS-601 **40 mg** BID (3/1) + cetuximab ERAS-601 **20 mg** BID (3/1) + cetuximab

• 40 mg BID (3/1) was identified as the monotherapy MTD of ERAS-601¹

• Pts with progressing chordoma were enrolled in the ERAS-601 80 mg TIW^c monotherapy, ERAS-601 40 mg BID BID (3/1) + cetuximab combination therapy groups

^a Orally, twice daily for 21 days followed by a 7-day break (3 weeks on, 1 week off), on a 28-day treatment cycle ^b Cetuximab: 500 mg/m² every 2 weeks; ^c TIW: BID 3 times per week

Chordoma Pt Enrollment & Baseline Characteristics

		Sa	f ety-Evaluable (n %)	Efficacy-Eval	uable (n %)
ERAS-601 80 mg TIW monotherapy			1 (100%)	1 (100%)	
ERAS-601 40 mg BID (3/1) monotherapy		1 (100%)	1 (100%)		
ERAS-601 40 mg BID (3/1) + cetuximab		11 (100%)	11 (100%)		
	Monotherapy (N = 2)	Combination (N = 11)		Monotherapy (N = 2)	Combination (N = 11)
Median age (range)	62 (60, 64)	60 (21, 74)	ECOG (n %)		
Sex (n %)			0	0	7 (63.6)
Male	1 (50)	6 (54.5)	1	2 (100)	4(36.4)
Female	1 (50)	5 (45.5)	# lines of prior system	r systemic therapy (n %)*	
Race (n %)			Median (min,max)	3.0 (3, 3)	1.0 (1, 3)
Black or African	0	1 (9.1)	1	0	5 (62.5)
American			2	0	2 (25.0)
White	0	9 (81.8)	3	1 (100)	1 (12.5)
Not reported	1 (50)	0			


Abbreviations – BOR: best overall response; CBR: clinical benefit rate; DLT: dose limiting toxicity; Combination: ERAS-601 40 mg BID (3/1) + cetuximab; Monotherapy: ERAS-601 80 mg TIW and ERAS-601 40 mg BID (3/1); MTD: maximum tolerated dose; PD: progressive disease; PR: partial response; PMR: partial metabolic response; RT: Radiation therapy; SAE: serious adverse event; SD: stable disease; SUV: standard uptake value; TEAE: Treatmentemergent adverse event; * four pts did not receive prior systemic therapy


1 (9.1)

Monotherapy (N = 2)	Combination (N = 11)				
62 (60, 64)	60 (21, 74)				
1 (50)	6 (54.5)				
1 (50)	5 (45.5)				
Race (n %)					
0	1 (9.1)				
0	9 (81.8)				
	Monotherapy (N = 2) 62 (60, 64) 1 (50) 1 (50)				


1 (50)

Other





(3/1) monotherapy, or ERAS-601 40 mg



Dtc ovporioncing at least one (p.%)	Monotherapy	Combination (N = 11)	
Pts experiencing at least one, (n %)	(N = 2)		
TEAEs	2 (100)	11 (100)	
Grade 3 or higher	1 (50)	7 (63.6)	
TEAEs in ≥ 25% of pts			
Dermatitis acneiform	0	8 (72.7)	
Fatigue	0	7 (63.6)	
Diarrhea	0	6 (54.5)	
Oedema peripheral	2 (100)	4 (36.4)	
Paronychia	0	6 (54.5)	
Dry skin	0	5 (45.5)	
Skin infection	0	5 (45.5)	
Nausea	0	4 (36.4)	
Skin fissures	0	4 (36.4)	
Stomatitis	0	4 (36.4)	
Vomiting	0	4 (36.4)	
ALT increased	0	3 (27.3)	
AST increased	0	3 (27.3)	
Rash maculo-papular	0	3 (27.3)	
TEAEs related to ERAS-601 or cetuximab	2 (100)	11 (100)	
Grade 3 or higher	0	6 (54.5)	
TRAEs leading to ERAS-601 discontinuation	1 (50)	0	
TRAEs leading to ERAS-601 interruption	0	8 (72.7)	
TRAEs leading to ERAS-601 dose reduction	0	1 (9.1)	
Treatment-emergent SAE	1 (50)	4 (36.4)	
Treatment-emergent SAE related to ERAS-601 or cetuximab	0	1 (9.1)	
All deaths (n %)	1 (50)	0	
DLT	0	0	

Overall data suggest that the ERAS-601 regimens were tolerable:


ERAS-601 TIW 80 mg and ERAS-601 BID (3/1) 40 mg monotherapies

• Both pts suffered from oedema peripheral at Grade 1-2


ERAS-601 40 mg BID (3/1) + cetuximab combination

- No Grade 4 or 5 TEAEs were reported
- Grade 3 TRAEs for ERAS-601 were reported in 5 (45.5%) pts; dermatitis acneiform, rash, rash maculopapular (n=1 each), skin infection (n=2)
- TRAEs leading to ERAS-601 dose interruption in ≥ 2 pts were rash (50.0%) and increased LFTs (27.3%)

MRI and PET Scans of Pt with Clival Chordoma 5 days prior to treatment




21.1 mm




Baseline SUV = 6.1

- 43-year-old pt with chordoma, received 4 resections and cisplatin/RT prior to enrollment
- ERAS-601 BID (3/1) + cetuximab combination therapy led to PMR by 52 days, and later a confirmed RECIST PR; the pt remains on study for over 1 year
- AEs were fatigue, diarrhea, acneiform rash


52 days post treatment start





PMR SD 17.2 mm (-18%) SUV = 3.4 (-44%)

Results



- ERAS-601 + cetuximab showed acceptable preliminary safety and tolerability
- •The most common toxicities associated with ERAS-601 + cetuximab were dermatologic, consistent with EGFR inhibition, reversible, and managed by dose interruptions and reductions

References

1.Sharifina (2023). Nat. Commun. 2.McKean, M. (2023). Cancer Res.

The authors would like to thank the patients, families, and caregivers. The authors also thank Hina Patel, Executive Director of Safety Science at Erasca, Inc.

Poster support was provided by MHJenkins Science Writing, LLC

Acknowledgments



Copies of this poster obtaine through Quick Response (QR) Code are for personal use onl ind may not be reproduced hout permission from ASCO or the author of this poster